Inhaled corticosteroids and long term outcome in adults with asthma

The concept that treatment with inhaled corticosteroids (ICS) may improve long term lung function by reversing or minimising the effects of airway remodelling remains an attractive one but, until now, unproven. It is therefore with much interest that we read the publications of two observational studies by Lange et al and by Dijkstra et al. Both groups of authors hypothesised that asthmatic individuals continuously treated with ICS would have a less pronounced decline in forced expiratory volume in 1 second (FEV₁) than those not treated with ICS, and their studies indeed suggest that long term treatment with ICS in asthmatic adults is associated with a more favourable decline in FEV₁ with age compared with the natural course of the disease. Obviously, the most interesting next question is to what extent further improvement in FEV₁ is possible. Unfortunately neither study addressed the issue of possible additional anti-inflammatory treatment. The assessment of FEV₁ after maximal bronchodilation and a course of systemic corticosteroids in these groups of patients would have been most interesting because it might show the maximal attainable functional outcome in adults who have had asthma for many years. Similarly, one could study growth of lung function in childhood and adolescence to assess whether this is affected by asthma and can be reversed by anti-inflammatory treatment. Lange et al, Dijkstra et al, and the accompanying editorial by Ernst4 refer to the CAMP3 study which showed that ICS treatment may not even improve FEV₁ in children with mild asthma compared with placebo. The CAMP study did indeed assess lung growth from postbronchodilator FEV₁, as the primary outcome variable, but it lacked the proper design to address this issue fully, because bronchodilation was not maximal and ICS treatment was started in a daily dose of 400 μg and tapered off or stopped based on symptoms. Because treatment based on symptoms does not take into account of—and is likely to underestimate—the degree of inflammation, such a study design is probably biased towards underestimation of the maximal attainable level of function.

In our own study we observed that FEV₁ after maximal bronchodilation was normalised in children with moderately severe asthma who continued to inhale 600 μg budesonide daily, and also when they had become completely asymptomatic. Because treatment based on symptoms does not take into account of—and is likely to underestimate—the degree of inflammation, such a study design is probably biased towards underestimation of the maximal attainable level of function. If you have a burning desire to respond to a paper published in Thorax, why not make use of our “rapid response” option?

Log on to our website (www.thoraxjn
l.com), find the paper that interests you, and send your response via email by clicking on the “elletors” option in the box at the top right hand corner of the homepage. Providing it isn’t libelous or obscene, it will be posted within seven days. You can also view responses by others on our homepage. The editors will decide as before whether to also publish it in a future paper issue.

P J F Merkus, J C de Jongste
Sophia Children’s Hospital, Erasmus University Medical Centre, Rotterdam, The Netherlands

Correspondence to: Dr P J F M Merkus, Sophia Children’s Hospital, Erasmus University Medical Centre, Rotterdam 2015 GJ, The Netherlands, p.j.m.merkus@erasusmc.nl

Competing interests: none declared.

References

Susceptibility to high altitude pulmonary oedema: role of ACE and ET-1 polymorphisms

High altitude pulmonary oedema (HAPE) is a severe form of altitude illness that develops in travellers on rapid ascent to or physical exertion at altitudes of >2500 m. The disease is characterised by pulmonary hyper tension, unevent vasoconstriction, and over perfusion which is thought to cause stress failure of pulmonary capillaries leading to alveolar flooding.2 Since uneven pulmonary vasoconstriction appears to play an important part in the development of HAPE, the genes involved in maintaining pulmonary vascular tone—for example, angiotensin converting enzyme (ACE) and endothelin-1 (ET-1)—could be possible candidates for HAPE. Earlier studies showed that the selective pressure of hypobaric hypoxia acted in favour of those alleles of ACE and ET-1 which were beneficial in maintaining a healthy state at high altitude.3,4 On the other hand, unfavourable alleles are likely to contribute to the susceptibility to HAPE. This hypothesis is also supported by an earlier report on the allelic variants of endothelial nitric oxide synthase gene.5

We therefore investigated ACE insertion/deletion (I/D) (GenBank accession no X62855) and ET-1 5'-untranslated region (UTR) microsatellite (CT)n, (CA)n (GenBank accession no J05008), −3A/−4A (rs10478694), G2288T (rs2070699), and Lys198Asn (rs5370) polymorphisms in 64 patients with HAPE (HAPE-p) and 53 healthy individuals (HAPE-r). The HAPE-r were healthy individuals who had climbed 2–3 times to altitudes greater than 3500 m and carried out routine strenuous physical activities without suffering from HAPE in contrast to the HAPE-p group suffered from HAPE on their very first visit. The study groups consisted of age matched (30–40 years) individuals of the same ethnicity. An institutional review committee approved the investigations and all subjects gave informed consent.

HAPE was diagnosed on the basis of the criteria described earlier.2 After recovery the HAPE-p were examined to exclude the possibility of any previous cardiopulmonary diseases. The subjects were genotyped for the five polymorphisms of the two genes using primers and conditions shown in table S1 (available online at http://www.thoraxjnln.com/ supplemental). The plasma ACE levels were measured by a kinetic method using N-[2-furyl(acryloyl)]-Phe-Gly-Gly as substrate. The plasma ET-1 levels were determined by ELISA (Assay Designs, Ann Arbor, USA). SPSS statistical software for Windows (release 10), EPIINFO 6, and SNP Alyze program (Version 3.1, Dynacom, Mobara-shi, Japan) were used to perform the statistical analysis.

The mean (SD) ACE activity and ET-1 levels were significantly higher in HAPE-p than in HAPE-r (84.6 (26.2) vs 40.7 (12.1) U/l and 8.0 (2.5) vs 3.5 (0.7) pg/ml, respectively; both p<0.0001). Furthermore, a direct relationship was observed between ACE activity and ET-1 levels in HAPE-p and HAPE-r (r = 0.31, p = 0.03 and r = 0.32, p = 0.02, respectively), which reflects their interaction. ACE generates angiotensin II which induces ET-1 transcription and secretion in vitro in a variety of cell types including endothelial and vascular smooth muscle cells.6 ET-1 is also involved in the regulation of ACE activity in vivo independently of ACE expression.7

The polymorphisms were Hardy-Weinberg equilibrium in both groups and are shown in table 1. The ID+DD and GT+TT genotypes of ACE I/D and ET-1 G2288T polymorphisms were over represented in HAPE-p (p = 0.03 and p = 0.002, respectively), with D and T alleles being more frequent in HAPE-p than HAPE-r. The (CT)n, (CA)n repeats were segregated and recognised as shorter (13–30) and longer (31–45) based on our earlier observation.2 However, unlike in our previous report, the shorter and longer repeats did not correlate with ET-1 levels. Analysis of the possible genotype combinations between the five polymorphisms showed that there were significantly fewer genotype combinations II/II and I/GG and II/GG in HAPE-p than in HAPE-r (p = 0.02 and p = 0.002, respectively). The longer repeats/
to high altitude present study and earlier reports on adaptation the susceptibility to HAPE. The findings of the p = 0.01). Our findings support the hypothesis (1% was significantly less in HAPE-p than in HAPE-r Lys198Lys genotype combination within ET-1 polymorphisms and their combinations in the HAPE-p and HAPE-r

<table>
<thead>
<tr>
<th>Genotypes/genotype combinations*</th>
<th>HAPE-p (n = 64)</th>
<th>HAPE-r (n = 53)</th>
<th>χ²</th>
<th>p value</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>18 (28)</td>
<td>23 (43)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DD</td>
<td>34 (53)</td>
<td>21 (40)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>12 (19)</td>
<td>9 (17)</td>
<td>5.10</td>
<td>0.07</td>
<td>1.94 (1.08 to 3.50)</td>
</tr>
<tr>
<td>ID-DD</td>
<td>46 (72)</td>
<td>30 (57)</td>
<td>4.91</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>ET-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longer repeats</td>
<td>17 (27)</td>
<td>19 (35)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shorter repeats</td>
<td>47 (73)</td>
<td>34 (65)</td>
<td>1.15</td>
<td>0.28</td>
<td>1.46 (0.80 to 2.66)</td>
</tr>
<tr>
<td>–3A/–3A</td>
<td>44 (69)</td>
<td>35 (66)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>–3A/–4A</td>
<td>20 (31)</td>
<td>18 (34)</td>
<td>0.21</td>
<td>0.65</td>
<td>0.87 (0.48 to 1.58)</td>
</tr>
<tr>
<td>GT</td>
<td>15 (23)</td>
<td>23 (43)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>37 (58)</td>
<td>22 (42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GT-TT</td>
<td>12 (19)</td>
<td>8 (15)</td>
<td>9.09</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Lys198lys</td>
<td>49 (77)</td>
<td>30 (57)</td>
<td>9.05</td>
<td>0.002</td>
<td>2.53 (1.37 to 4.65)</td>
</tr>
<tr>
<td>Lys198Asn</td>
<td>22 (34)</td>
<td>17 (31)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asn198Asn</td>
<td>32 (50)</td>
<td>27 (52)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE-ET-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/Longer repeats</td>
<td>1 (1)</td>
<td>4 (8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining combinations</td>
<td>63 (99)</td>
<td>49 (92)</td>
<td>5.70</td>
<td>0.02</td>
<td>0.12 (0.01 to 0.95)</td>
</tr>
<tr>
<td>II/–3A/–3A</td>
<td>13 (21)</td>
<td>15 (28)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining combinations</td>
<td>51 (79)</td>
<td>38 (72)</td>
<td>1.32</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>II/GG</td>
<td>5 (7)</td>
<td>12 (23)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining combinations</td>
<td>59 (93)</td>
<td>41 (77)</td>
<td>10.04</td>
<td>0.002</td>
<td>0.25 (1.0 to 6.2)</td>
</tr>
<tr>
<td>II/Lys198lys</td>
<td>9 (14)</td>
<td>8 (16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remaining combinations</td>
<td>55 (86)</td>
<td>45 (84)</td>
<td>0.15</td>
<td>0.69</td>
<td>0.85 (0.39 to 1.86)</td>
</tr>
</tbody>
</table>

Table 1 Distribution of ACE I/D and ET-1 –3A/–4A, G2288T and Lys198Asn polymorphisms and their combinations in the HAPE-p and HAPE-r

Lys198Lys genotype combination within ET-1 was significantly less in HAPE-p than in HAPE-r (1% vs 9%, odds ratio 0.10 (95% CI 0.01 to 0.82), p = 0.01). Our findings support the hypothesis that ACE and ET-1 polymorphisms have a role in the susceptibility to HAPE. The findings of the present study and earlier reports on adaptation to high altitude1-6 together indicate that ACE and ET-1 genes are significant in high altitude physiology.

In conclusion, this study showed that ACE and ET-1 variants have independent and interactive roles in the susceptibility to HAPE. Higher ACE activity and ET-1 levels correlated with HAPE. The ACE I/D and ET-1 G2288T polymorphisms emerged as noteworthy variants showing association with HAPE. Owing to the small sample size, the difference in representation of the polymorphisms and their correlation with biochemical parameters did not reach greater statistical significance; in particular, we consider our data on the genotype combinations between the polymorphisms of the two genes to be preliminary. Nevertheless, since HAPE samples are difficult to obtain, the findings of this study are important and warrant confirmation in a larger sample. The results of this study may find application in identifying individuals with a predisposition to HAPE.

Acknowledgements

The authors thank Ven Thubten Choegyal, Choegyal, Ladakh Heart Foundation who helped with the collection of blood samples and Professor S K Bhramachari for his support and encouragement.

References


NSIP in a curry sauce factory worker

Curry powder and ground pepper are commonly used spices in many countries of the world. Although a case of bronchiolitis obliterans organising pneumonia has been reported in a worker who inhaled spice dust in a potato chip factory,1 we report the first case of non-specific interstitial pneumonia (NSIP)2 with bronchiolar lesions associated with curry powder and ground pepper.

A 50 year old male smoker (20 pack-years) developed a cough with sputum and shortness of breath on both working days and non-working days and was admitted to our hospital 1 month after developing the symptoms. He had worked in a factory that produced curry sauce for 13 years. His job was to carry sacks filled with curry powder (containing a mix of ground spices) and ground pepper on his shoulders and to empty them into a large curry sauce cooker without any equipment to protect against dust inhalation.

Physical examination on admission revealed inspiratory crackles in the bilateral lower lungs without digital clubbing. Serum markers for interstitial pneumonia, surfactant protein D (SP-D), and KL-6 were raised to 2410 ng/ml and 5570 U/ml, respectively. A high resolution computed tomographic (HRCT) scan of the chest revealed multiple irregular consolidations along with bronchovascular bundles and, in the subpleural lesions, trivial pleural effusion and cystic air spaces in the bilateral apex portions (fig 1A). Bronchoalveolar lavage was performed; the total cell count was 4.1×10⁶/ml with 23.8% macrophages, 70.4% lymphocytes, 0.2% neutrophils, 0.6% eosinophils, and 3.0% basophils. The CD4⁺/CD8⁺ lymphocyte ratio was 0.94 and pathogenic organisms were not detected.

Specimens obtained by video assisted thoracoscopic surgery from the right lung revealed a cellular and fibrosing NSIP with intrapulmonary granulomas andclusions seen on the HRCT scan had spontaneously resolved. Lymphocyte stimulation tests (LST) using the patient's own lymphocytes and peripheral blood lymphocytes were positive for the curry powder, ground black pepper, and ground

R Charu, T Stobdan, R B Ram, A P Khan, M A Qadar Pasha

Institute of Genomics and Integrative Biology, Delhi, India

T Norboo

Ladakh Institute of Prevention, Leh, Ladakh, J&K, India

R Charu, F Afrin

Department of Biotechnology, Hamdard University, New Delhi, India

Correspondence to: Dr M A Qadar Pasha, Institute of Genomics and Integrative Biology, Maul Road, Delhi-110 017, India; qapasha@igib.res.in

R Charu and TS contributed equally to this work.

doi: 10.1136/thx.2006.066019

This work was funded by the Council of Scientific and Industrial Research.

Competing interests: none.

Details of the primers and conditions for genotyping the five polymorphisms are shown in table S1 available on the Thorax website at http://www.thoraxjnl.com/supplemental.

www.thoraxjnl.com
Susceptibility to high altitude pulmonary oedema: role of ACE and ET-1 polymorphisms

R Charu, T Stobdan, R B Ram, A P Khan, M A Qadar Pasha, T Norboo and F Afrin

Thorax 2006 61: 1011-1012
doi: 10.1136/thx.2006.066019

Updated information and services can be found at:
http://thorax.bmj.com/content/61/11/1011.2

These include:

References
This article cites 6 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/61/11/1011.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/